Dr. Manuel Bernal Sprekelsen, Professor of Otorhinolaryngology at the Medical University of Valencia, has developed a large part of his professional career as head of the Hospital Clinic of Barcelona, where he has moved to offer his services at the Hospital Quirónsalud Valencia with the objective of offering patients minimally invasive endoscopic techniques for the treatment of nose and sinus pathologies of which the doctor is one of the pioneers worldwide.

El doctor Manuel Bernal durante la intervenciónEl doctor Manuel Bernal durante la intervención

Endoscopic surgery of the nose and sinuses addresses acute or chronic diseases in which sinus drains have been blocked, retaining mucus or pus without responding to medical treatment. "That's when the affected paranasal sinuses are repainted through the nostrils without the need to make external incisions (on the face) that later leave scars. One of the chronic sinusitis that causes greater discomfort is the one that is accompanied by polypoid tissue formation that obstructs nasal breathing like the one that has been addressed in this surgery, "explains Dr. Bernal.

This type of surgery is also the most indicated for the approach of the turbinates and the obstruction of the lacrimal through the nose with the help of endoscopes of cold light that facilitate illuminating the nasal passages to visualize all the surgical maneuvers.

Transoral microsurgery to fight cancer of the larynx

Likewise, Dr. Manuel Bernal is one of the leading figures in the approach to cancer of the larynx by means of transoral microsurgery with a carbon dioxide laser in which the precision and coagulation capacity of the carbonic laser is combined with microscopic control and provides very good oncological results. functional Their results in early laryngeal tumors are totally comparable to those of partial external surgery, with local control equal to or superior to that achieved with radiotherapy. For this reason, transoral laser microsurgery is now considered a first-line treatment for early laryngeal cancer, offering a survival rate of over 90% at five years, as well as the preservation of the larynx.